Date: 2015-05-27
Type of information: Collaboration agreement
Compound: companion diagnostic assay for use with PEGPH20
Company: Halozyme Therapeutics (USA - CA) Ventana Medical Systems,(USA), a member of the Roche Group (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On May 27, 2015, Halozyme Therapeutics and Ventana Medical Systems announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme\'s investigational new drug, PEGPH20. The Ventana assay will be used to identify high levels of hyaluronan (HA). HA is a glycosaminoglycan – a chain of natural sugars distributed throughout human tissue – that can accumulate around cancer cells. Halozyme has announced plans for rollout of a global phase 3 clinical study in 2016 targeting metastatic pancreatic cancer patients with high HA levels using its PEGPH20 in combination with Abraxane® (nab-paclitaxel) and gemcitabine. Under the agreement, Ventana will develop an in vitro diagnostic (IVD), under design control, using Halozyme\'s proprietary HA binding protein, with the intent of submitting it for regulatory approval in the United States, Europe and other countries.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
